Czech National Bank Acquires 1,039 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Czech National Bank raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 2.8% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 38,425 shares of the medical research company’s stock after acquiring an additional 1,039 shares during the period. Czech National Bank’s holdings in IQVIA were worth $6,774,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of IQV. GKV Capital Management Co. Inc. bought a new position in shares of IQVIA in the fourth quarter worth approximately $39,000. Lee Danner & Bass Inc. bought a new stake in IQVIA during the fourth quarter valued at approximately $44,000. Zions Bancorporation N.A. raised its position in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after buying an additional 85 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of IQVIA during the 4th quarter valued at $60,000. Finally, Thematics Asset Management purchased a new stake in shares of IQVIA during the 4th quarter valued at $76,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Price Performance

IQV stock opened at $139.06 on Tuesday. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm’s 50-day moving average price is $149.98 and its two-hundred day moving average price is $180.19. The stock has a market capitalization of $24.06 billion, a price-to-earnings ratio of 18.54, a PEG ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The firm had revenue of $3.83 billion for the quarter, compared to analysts’ expectations of $3.77 billion. During the same period in the previous year, the firm earned $2.54 earnings per share. The business’s revenue was up 2.5% compared to the same quarter last year. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research reports. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Stifel Nicolaus decreased their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Mizuho decreased their price objective on IQVIA from $210.00 to $190.00 and set an “outperform” rating on the stock in a report on Thursday, May 15th. HSBC cut IQVIA from a “buy” rating to a “hold” rating and decreased their price objective for the company from $260.00 to $160.00 in a report on Friday, April 25th. Finally, Barclays decreased their price target on shares of IQVIA from $170.00 to $165.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 7th. Eight investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $226.32.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.